GEICAM estará presente en el congreso ESMO23, celebrado en Madrid del 20 al 24 de octubre, con el siguiente póster de un estudio propio, que expondrá este sábado 21 de octubre el Dr. José Ángel García- Sáenz:

• Body Mass Index as a predictive factor for efficacy of taxane-based chemotherapy in early breast cancer patients.

Por otro lado, durante el congreso tendrán lugar las siguientes comunicaciones orales y pósteres de estudios con participación de GEICAM:

Comunicaciones orales:

• Invasive disease–free survival (iDFS) across key subgroups from the Phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC).
• Impact of body mass index and its change on survival outcomes in patients with early breast cancer: a pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials.

Pósteres:

• Cost-effectiveness of first line (1L) ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2− advanced breast cancer (ABC): analysis based on final overall survival (OS) results of MONALEESA-2 (ML-2) and PALOMA-2 (PAL-2).
• Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin (NadGC) in metastatic triple negative breast cancer (mTNBC).

Pósteres (Trial in Progress):

• Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01.
• A phase 3 randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2– early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1).
• EORTC BCG 1984 – NOBLE – Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer.

Más información y horarios